Cynomolgus monkey model of interleukin‐31‐induced scratching depicts blockade of human interleukin‐31 receptor A by a humanized monoclonal antibody

Citations Over TimeTop 10% of 2016 papers

Abstract

Scratching is an important factor exacerbating skin lesions through the so-called itch-scratch cycle in atopic dermatitis (AD). In mice, interleukin (IL)-31 and its receptor IL-31 receptor A (IL-31RA) are known to play a critical role in pruritus and the pathogenesis of AD; however, study of their precise roles in primates is hindered by the low sequence homologies between primates and mice and the lack of direct evidence of itch sensation by IL-31 in primates. We showed that administration of cynomolgus IL-31 induces transient scratching behaviour in cynomolgus monkeys and by that were able to establish a monkey model of scratching. We then showed that a single subcutaneous injection of 1 mg/kg nemolizumab, a humanized anti-human IL-31RA monoclonal antibody that also neutralizes cynomolgus IL-31 signalling and shows a good pharmacokinetic profile in cynomolgus monkeys, suppressed the IL-31-induced scratching for about 2 months. These results suggest that the IL-31 axis and IL-31RA axis play as critical a role in the induction of scratching in primates as in mice and that the blockade of IL-31 signalling by an anti-human IL-31RA antibody is a promising therapeutic approach for treatment of AD. Nemolizumab is currently under investigation in clinical trials.

Related Papers

• → Evaluation and Characterization of Mouse Scratching Behavior by a New Apparatus, MicroAct(2003)80 cited
• → Quantitative assessment of directed hind limb scratching behavior as a rodent itch model(2003)44 cited
• → Suppression of scratching-induced pleasurable sensation by compression nerve blocking and its association with itch relief(2017)7 cited
• → PROBLEMS OF HEAD‐SCRATCHING IN BIRDS(1961)23 cited
• [Analysis of scratching behavior in a picryl chloride induced atopic dermatitis model in mice].(2003)